JNJ
Johnson & Johnson
$253.04
+3.07
(+1.23%)
Mkt Cap
609.12B
Volume
7,516,376
52W Range
162.78-269.43
Sector
Healthcare
Beta
0.23
EPS (TTM)
8.65
P/E Ratio
29.25
Revenue (TTM)
97.93B
Rev Growth (5Y)
+2.3%
EPS Growth (5Y)
+11.5%
AlphaVal · Fair Value
What we estimate one share is worth
$206.78
Overvalued
moderate signal
22.4% above fair value
Modeled from cash flows & growth.
AlphaQuality · Grade
How strong & durable the business is
B+
Stable Earnings Power
79.5 / 100 composite
Steady, predictable earnings power — graded A–F vs. similar companies.
Company Description
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 94.19B | 88.82B | 85.16B | 79.99B | 78.74B | 82.58B | 82.06B | 81.58B | 76.45B | 71.89B | 70.07B | 74.33B |
| Net Income | 26.80B | 14.07B | 35.15B | 17.94B | 20.88B | 14.71B | 15.12B | 15.30B | 1.30B | 16.54B | 15.41B | 16.32B |
| EPS | 11.03 | 5.84 | 13.88 | 6.83 | 7.93 | 5.59 | 5.74 | 5.75 | 0.48 | 6.08 | 5.57 | 5.86 |
| Free Cash Flow | 19.70B | 19.84B | 18.25B | 17.18B | 19.76B | 20.19B | 19.92B | 18.53B | 17.78B | 15.54B | 15.82B | 14.76B |
| FCF / Share | 8.11 | 8.24 | 7.20 | 6.58 | 7.52 | 7.67 | 7.57 | 6.96 | 6.63 | 5.74 | 5.74 | 5.30 |
| Operating CF | 24.53B | 24.27B | 22.79B | 21.19B | 23.41B | 23.54B | 23.42B | 22.20B | 21.06B | 18.77B | 19.28B | 18.47B |
| Total Assets | 199.21B | 180.10B | 167.56B | 187.38B | 182.02B | 174.89B | 157.73B | 152.95B | 157.30B | 141.21B | 133.41B | 130.36B |
| Total Debt | 47.93B | 36.63B | 29.33B | 39.64B | 33.75B | 35.27B | 27.70B | 30.48B | 34.58B | 27.13B | 19.86B | 18.76B |
| Cash & Equiv | 19.71B | 24.11B | 21.86B | 12.89B | 14.49B | 13.98B | 17.30B | 18.11B | 17.82B | 18.97B | 13.73B | 14.52B |
| Book Value | 81.54B | 71.49B | 68.77B | 76.80B | 74.02B | 63.28B | 59.47B | 59.75B | 60.16B | 70.42B | 71.15B | 69.75B |
| Return on Equity | 0.33 | 0.20 | 0.51 | 0.23 | 0.28 | 0.23 | 0.25 | 0.26 | 0.02 | 0.23 | 0.22 | 0.23 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.31B | 24.06B | 24.56B | 23.99B | 23.74B | 21.89B | 22.52B | 22.47B | 22.45B | 21.38B | 21.39B | 21.35B |
| Net Income | 5.53B | 5.24B | 5.12B | 5.15B | 5.54B | 11.00B | 3.43B | 2.69B | 4.69B | 3.25B | 4.05B | 26.03B |
| EPS | 2.27 | 2.14 | 2.10 | 2.14 | 2.29 | 4.57 | 1.43 | 1.12 | 1.95 | 1.35 | 1.68 | 10.32 |
| Free Cash Flow | N/A | 1.47B | 5.47B | 8.38B | 2.48B | 3.38B | 4.84B | 5.71B | 4.66B | 2.85B | 6.27B | 6.52B |
| FCF / Share | N/A | 0.60 | 2.25 | 3.45 | 1.03 | 1.40 | 2.01 | 2.37 | 1.93 | 1.18 | 2.61 | 2.59 |
| Operating CF | N/A | 2.51B | 7.31B | 9.17B | 3.88B | 4.17B | 6.98B | 7.99B | 5.63B | 3.66B | 7.86B | 7.49B |
| Total Assets | N/A | 200.89B | 199.21B | 192.82B | 193.39B | 193.67B | 180.10B | 178.29B | 181.09B | 171.97B | 167.56B | 166.06B |
| Total Debt | N/A | 54.99B | 47.93B | 45.80B | 50.76B | 52.25B | 36.63B | 35.75B | 41.49B | 33.63B | 29.33B | 29.92B |
| Cash & Equiv | N/A | 21.69B | 19.71B | 18.23B | 18.58B | 38.47B | 24.11B | 19.98B | 24.88B | 25.47B | 21.86B | 19.73B |
| Book Value | N/A | 81.19B | 81.54B | 79.28B | 78.47B | 78.11B | 71.49B | 70.16B | 71.54B | 70.02B | 68.77B | 71.23B |
| Return on Equity | N/A | 0.06 | 0.06 | 0.06 | 0.07 | 0.14 | 0.05 | 0.04 | 0.07 | 0.05 | 0.06 | 0.37 |
JNJ News
The Portfolio That Gives You a $2,000 Raise Every Year
3 Dividend Stocks That Have Survived Every Market Crash in July
Here’s the Funding It Takes to Keep Learning Forever
Jim Cramer Says the Market Is “Dead Wrong” About These 5 Oversold Stocks
Can a Conservative Portfolio Really Generate $4,000 a Month in Retirement Income?
J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here's Why
Eli Lilly's $3.8bn psychedelics bet is built on British science
I Was Wrong About Johnson & Johnson: Upgrading To Hold (Rating Upgrade)
The Portfolio That Pays All Your Car Repairs For Life
Johnson & Johnson Posts Upbeat Q2: IM Momentum Building Into 2027, Says Bullish Analyst